Oasis Biotechnology

Oasis Biotechnology is a clinical-stage biopharmaceutical company focused on developing innovative RNA interference (RNAi) therapeutics. Based in Suzhou, China, the company leverages its proprietary GalNAc-siRNA delivery platform to target chronic diseases with high unmet medical needs, particularly in the cardiovascular and metabolic spaces. Their pipeline includes candidates for hyperlipidemia, hypertension, and chronic hepatitis B infection. Oasis aims to provide long-acting, highly specific treatments that improve patient compliance and outcomes compared to traditional small molecule therapies. The company is backed by leading venture capital firms including Matrix Partners China and GL Ventures.